The cell-based therapy market will grow significantly, supported by recent clarity in the FDA pathway, improved clinical outcomes as well as market entry by big pharma.
Market Insight: Oded Ben-Joseph, PhD and Echoe Bouta, PhD
The cell-based therapy market will grow significantly, supported by recent clarity in the FDA pathway, improved clinical outcomes as well as market entry by big pharma.
Recent advances in cell-based therapy technology and FDA approvals have demonstrated the feasibility of of treating difficult diseases. Given the progress, we examined recent market dynamics in a 3.5-year period starting in January 2015 by analyzing clinical trials, financing events, M&As and IPOs to assess the overall activity of the sector and interest by venture capitalists and strategic players
Macroeconomic uncertainty, confusion surrounding the diagnostic regulatory landscape, and the continuing post-COVID-19 pandemic hangover have all contributed to a stagnant, quiet period for mergers and acquisitions in the in vitro diagnostics space in the first half of 2024.
Read MoreOutcome Capital Life Science Market Pulse June 2024 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?